ZNF224 enhances the oncogenic function of p21 via p53 and AKT pathways in melanoma
The FEBS Journal · 2025
DOI: 10.1111/febs.70114 ↗Kurz gefasst
Fachartikel in der Zeitschrift The FEBS Journal, 2025. Verfasst von Leandra Sepe und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase Inhibitor p21, Melanoma, Tumor Suppressor Protein p53, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Expression of zinc finger protein 224 ( ZNF224 ) is deregulated in various hematological and solid cancers, where its high protein levels correlate well with faster progression and worse prognosis due to activation of oncogenic pathways involved in promoting cell growth and survival, inhibiting apoptosis, and sustaining invasion and metastasis. In previous works, we identified ZNF224 as one of the mediators of the transforming growth factor beta (TGF‐β)‐induced pro‐tumoral activities in melanoma. In the present study, we thoroughly investigated the molecular mechanisms underlying the oncogenic role of ZNF224 in this kind of cancer. We demonstrated that ZNF224 overexpression caused increased cell growth and reduced drug‐mediated apoptosis by enhancing the dysregulated function of cyclin‐dependent kinase inhibitor 1 [p21(CIP1/WAF1), also known as CDKN1A]. We provide strong evidence that ZNF224 overexpression in melanoma cell lines positively modulated p21(CIP1/WAF1) gene transcription in a p53‐dependent manner and enhanced AKT‐triggered p21(CIP1/WAF1) oncogenic effects through its protein cytosolic retention, inhibiting apoptosis and favoring cell proliferation. Analysis of transcriptomic data from human melanoma tissue samples confirmed a close relationship between p21(CIP1/WAF1) and ZNF224 in cells, at least as long as p53 functionality is maintained. The tumorigenic molecular mechanism involving ZNF224, identified in this study, provides new insights into understanding melanoma development and progression, breaking ground in the research for new therapeutic tools.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.
- Ceinge Advanced Technologies, Naples, Italy.
- Biomunex Pharmaceutical - Bioincubateur Paris Biotech Santé, Hôpital Cochin, Paris, France.
- Department of Sciences and Technologies, University of Sannio, Benevento, Italy.
ORCID-Profile: Elena Cesaro
Zitieren
APA
Sepe, L., Candia, U., Sasso Del Verme, D., Toscano, E., Toriello, M., Sodaro, G., Rapuano, R., Romano, S., Grosso, M., Paolella, G., Lupo, A., Costanzo, P., & Cesaro, E. (2025). ZNF224 enhances the oncogenic function of p21 via p53 and AKT pathways in melanoma. The FEBS Journal. https://doi.org/10.1111/febs.70114
Vancouver
Sepe L, Candia U, Sasso Del Verme D, Toscano E, Toriello M, Sodaro G, et al. ZNF224 enhances the oncogenic function of p21 via p53 and AKT pathways in melanoma. The FEBS Journal. 2025. doi:10.1111/febs.70114
BibTeX
@article{Sepe2025,
author = {Sepe, Leandra and Candia, Umberto and Sasso Del Verme, Dario and Toscano, Elvira and Toriello, Marianna and Sodaro, Gaetano and Rapuano, Roberta and Romano, Simona and Grosso, Michela and Paolella, Giovanni and Lupo, Angelo and Costanzo, Paola and Cesaro, Elena},
title = {ZNF224 enhances the oncogenic function of p21 via p53 and AKT pathways in melanoma},
journal = {The FEBS Journal},
year = {2025},
doi = {10.1111/febs.70114}
}
EUVIMED